Supplementary Online Content


**eFigure 1.** Effect of Anakinra on DLQI

**eFigure 2.** Effect of Anakinra in 2 Patients

This supplementary material has been provided by the authors to give readers additional information about their work.
Changes of scoring for each of the questions of DLQI at week 12 in the placebo arm and in the anakinra arm are shown. Comparisons close to significance between groups: *p: 0.053; **p: 0.058
eFigure 2. Effect of Anakinra in 2 Patients

Representative lesions of the intergluteal area are shown for one patient at baseline and after 12 weeks of treatment and of the left femoinguinal fold for another patient at baseline and at 24 weeks (i.e. 12 weeks after stop of therapy).